Trivalent Live Attenuated Vaccines for Bacterial Acute Otitis Media
- Institution
- ST. JUDE CHILDREN'S RESEARCH HOSPITAL, TN
- Principal investigator
- Jason W. Rosch
- Funding
- $221K
- Duration
- 2024–2026
Moonbase score
Still being scored
Abstract
Summary Clinically, AOM is the leading reason for pediatrician visits and antibiotic usage by children. The predominant causative agents of AOM are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. While currently licensed capsule-based vaccines have dramatically lowered in the incidence of invasive pneumococcal disease, the incidence of mucosal infections such as AOM has remained relatively unchanged. Likewise, non-typeable H. influenzae currently predominates the AOM landscape following introduction of the Hib vaccine. Additionally complicating matters is the potential concern that a vaccine targeting an individual otopathogen may not reduce overall incidence of AOM due to the non-targeted pathogens becoming more predominant following the removal of an individual pathogen. We have engineered a safe, effective, and highly manipulatable platform for delivering protein epitopes to the mucosal surface to target multiple otopathogens simultaneously while engendering protective immunity at the mucosal surface. Leveraging a combinatorial approach for eliminating multiple AOM pathogen simultaneously using a live vaccine platform to maximize mucosal antibody responses represents a novel strategy for reducing the burden of AOM in children.
LOADING MOONBASE SCORE
Questions for ST. JUDE CHILDREN'S RESEARCH HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · ST. Jude Children'S Research HospitalNot yet scored
Characterization of TCS11 in Streptococcus pneumoniae
Elisa B H Margolis · $221K · 2024–2026
- NIH · ST. Jude Children'S Research HospitalNot yet scored
Consequences of Direct Viral-Bacterial Interactions
Jason W. Rosch · $487K · 2022–2026
- NIH · Boston Children'S HospitalNot yet scored
Collateral Consequences of Enabler Genotypes in Antibiotic Treatment Failure.
Jason W. Rosch · $771K · 2022–2026